Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma

Trial Profile

Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2019

At a glance

  • Drugs Cytarabine (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Folinic acid; Methotrexate; Prednisone; Rituximab; Vincristine
  • Indications Anaplastic large cell lymphoma; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms REBOOT; REBOOT ABLY
  • Most Recent Events

    • 11 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 28 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top